Clinical trials
catalyst calendar across sponsors →Studies where QTTB is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional
Held by 10 tracked-famous managers (Point72 Asset Management, L.P., RENAISSANCE TECHNOLOGIES LLC, JANE STREET GROUP, LLC, CITADEL ADVISORS LLC, MARSHALL WACE, LLP, +5 more) · FINRA short interest 3.8 days to cover (settled 2026-07-31) · insider 90d: 4 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)NCT06018428Part A: Mean relative percent change in SALT scoreOpen-label · Treatment | Phase 2 | Active, not recruiting | Drug: bempikibart (ADX-914) | Alopecia Areata | 75 | Jun 2026 | 2026-05-08 |
| Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)NCT05509023Part A only: Safety parameters including incidence of serious adverse events and adverse events of special interestRandomized · Triple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: ADX-914, Placebo | Atopic Dermatitis | 102 | Dec 2024 | 2024-10-03 |
| Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult VolunteersNCT04485481Number of subjects with adverse eventsRandomized · Quadruple-masked · Other | Phase 1 | Completed | Drug: ADX-914, Placebo, ADX-914, Placebo | Safety Issues | 42 | 2022-01-12actual | 2022-07-28 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19